United States Patent 8,940,744: Scope, Claim Strength, and Patent-Landscape Implications
What is US Patent 8,940,744 actually claiming?
US 8,940,744 is structured as a classic “compound plus downstream protection” patent. The claims you provided cover:
-
A genus of stereochemically defined small-molecule compounds (Claim 1) selected from a set of closely related structures that share a common scaffold:
- pyrazolo[3,4-d]pyrimidine core bearing an anilide-like “4-amino-3-(2-fluoro-4-phenoxyphenyl)” substitution
- connected to a piperidine carbonyl and then to a substituted pent-2-enenitrile side chain
- where the piperidine stereochemistry is controlled (3R or 3S)
- and the side-chain stereochemistry includes E/Z isomerism (Claim 1 and dependent claims)
- and the basic amine substituent on the side chain varies (methylpiperazine, piperazine, trimethylpiperazine, dimethylpiperazine, and oxetan-3-yl piperazine variants)
- and salts are included (Claim 1)
-
Species-level dependents that narrow the genus by fixing:
- piperidine chirality (3R or 3S)
- the side-chain E/Z configuration
- the amine substituent identity (methylpiperazine vs piperazine vs trimethylpiperazine vs dimethylpiperazine vs oxetane-3-yl piperazine)
- and in some places, the chirality within the substituted piperazine ring (e.g., “(3S,5R)-3,4,5-trimethylpiperazin-1-yl” and “(3S,5R)-3,5-dimethylpiperazin-1-yl”)
-
Compositions (Claim 13 and dependents): pharmaceutical composition comprising a compound of Claim 1 plus excipient.
-
Method-of-treatment (Claim 22 and dependents): broad therapeutic use across autoimmune, inflammatory, and cancer categories, then narrowed in dependent claims to specific autoimmune/inflammatory indications.
-
A synthetic process claim (Claim 30): a route that attaches different “Rc” aldehydes or amino-acid equivalents to core intermediates and includes optional steps:
- optional salt formation/free base
- optional stereoisomer separation
- optional E/Z isomer separation
The net effect: US 8,940,744 seeks to cover the full commercialization pipeline for a specific chemical family: manufacturing, formulation, and clinical use.
How broad is Claim 1’s compound “genus”?
Claim 1 is a selection from multiple compound entries, grouped by the variable “Z” region in your transcription (the substituted piperazine end group and whether the piperidine carbon is R or S, plus E/Z and salt coverage).
Core structural commonality in Claim 1
Across all the listed compounds in Claim 1, the conserved elements include:
- Pyrazolo[3,4-d]pyrimidine system
- substitution:
- 4-amino
- 3-(2-fluoro-4-phenoxyphenyl)
- a piperidine-1-yl carbonyl linkage
- a pent-2-enenitrile scaffold (implies a vinyl stereocenter and thus E/Z)
- substitution at the “4-position” by a piperazine-derived amine moiety
Main variables Claim 1 sweeps
The claim expands scope through four orthogonal “knobs”:
-
Piperidine stereochemistry
- (3R) vs (3S) or mixture (explicitly included)
-
E/Z isomerism of the pent-2-enenitrile
- “an individual E or Z isomer of any of the above compounds” (explicitly included)
- mixtures are included through the mixture language plus dependent claims
-
Substituted piperazine identity (end-group diversity)
Included examples you listed:
- 4-methylpiperazin-1-yl
- piperazin-1-yl
- (3S,5R)-3,4,5-trimethylpiperazin-1-yl
- (3S,5R)-3,5-dimethylpiperazin-1-yl
- 4-(oxetan-3-yl)piperazin-1-yl
-
Salts
- “and/or a pharmaceutically acceptable salt of any of the above compounds.”
Practical scope read-through
Claim 1 is not a single compound but a family that is:
- stereochemistry-rich (R/S and E/Z)
- end-group rich (multiple piperazine variants, including oxetane)
- salt-inclusive
- mixture-inclusive
That breadth matters for enforcement. A competitor that makes or sells any one of these stereochemical variants or salts for the covered scaffold is plausibly within Claim 1, even if they do not sell the exact same crystalline form or mixture ratio (as long as it falls into the claimed compound identity categories like “mixture of” and/or “individual E or Z isomer”).
What do the dependent claims do to reinforce claim coverage?
Dependent claims largely do two things: (i) they pin down species inside the genus and (ii) they set up fallback positions for validity or non-infringement arguments.
Key reinforcement by stereochemical and end-group narrowing
Your provided dependents cover, by example:
- Claim 2: “where *C is (R), (S), or a mixture of (R) and (S); or an individual E or Z isomer …; and/or a pharmaceutically acceptable salt”
- Claims 3-5: E/Z isomer explicit for a given piperidine chirality and then mixture forms
- Claims 6-9: trimethylpiperazine and dimethylpiperazine end-group species, again tied to E/Z and R/S patterns
- Claims 10-12: oxetan-3-yl piperazine end-group species, plus E/Z and chirality
- Claims 13-21: composition dependents for the same set of species
Commercial implication
If Claim 1’s broad genus is attacked, the dependent species claims can:
- remain enforceable as narrower fallbacks
- shift the infringement question from “does the product belong to a genus?” to “does it match a specific stereochemical and end-group species?”
How wide is the therapeutic-use coverage?
Claim 22 sets an unusually broad therapeutic-use umbrella.
Claim 22: autoimmune + inflammatory + cancer categories
Claim 22 covers method-of-use for a patient with diseases chosen from:
Autoimmune disease list includes (non-exhaustive transcription matches):
inflammatory bowel disease, arthritis, lupus, myasthenia gravis, Graves' disease, Sjogren's syndrome, Sjogren's dry eye, non-Sjogren's dry eye disease, multiple sclerosis, Guillain-Barre syndrome, ankylosing spondylitis, idiopathic thrombocytopenic purpura, scleroderma, warm autoimmune hemolytic anemia, Wegener's granulomatosis, psoriasis.
Inflammatory disease list includes:
asthma, colitis, conjunctivitis, Behcet's disease, atopic dermatitis, uveitis, or eczema.
Cancer list includes (as transcribed):
diffuse large B cell lymphoma, follicular lymphoma, chronic lymphocytic lymphoma, chronic lymphocytic leukemia, B-ALL, B-cell prolymphocytic leukemia, small lymphocytic lymphoma (SLL), multiple myeloma, B-cell non-Hodgkin lymphoma, lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, mantle cell lymphoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, burkitt lymphoma/leukemia, lymphomatoid granulomatosis.
Dependent claim narrowing
- Claim 23 narrows to autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, lupus, uveitis, myasthenia gravis, warm autoimmune hemolytic anemia, Wegener's granulomatosis, Sjogren's disease/dry eye variants, psoriasis, and asthma.
Composition-to-method linkage
Claims 22-29 are framed as:
- administering a pharmaceutical composition comprising excipient and a therapeutic amount of a Claim 1 compound or salt.
This ties infringement to the formulation and use rather than just chemical presence.
What protection is provided for manufacturing? (Claim 30)
Claim 30 is a process claim that captures multiple variants of synthesis by covering:
- reacting a compound of formula (1) with an aldehyde RcCHO, where Rc contains piperazine-derived substituents
- or reacting a compound of formula (2) with RcCH═C(CN)CO2H or RcCH═C(CN)COX, where X is a leaving group
- then optional steps:
- acid addition salt formation
- free base formation
- separation of individual stereoisomers
- separation of individual E and Z isomers
Scope consequences
A process claim can be a powerful barrier for generics and contract manufacturers because:
- it targets method-of-making
- it potentially captures both stereochemistry-aware and stereochemistry-separating workflows
In practice, the strength depends on:
- how clearly the claimed intermediates “formula (1)” and “formula (2)” map to the patented family
- whether common industrial routes do or do not intersect these steps
Your transcription includes the broad Rc catalog, explicitly tying it to:
- piperazin-1-yl
- 4-methylpiperazin-1-yl
- trimethylpiperazin-1-yl with specified stereochemistry
- dimethylpiperazin-1-yl with specified stereochemistry
- oxetan-3-yl piperazin-1-yl
So Claim 30 is not limited to one amine variant; it covers multiple end-group outcomes.
Claim coverage map: what product attributes fall inside?
The following table translates the claim language into enforceable product attributes.
| Attribute |
What Claim language includes |
Examples from your transcription |
| Piperidine stereochemistry |
(3R), (3S), or mixtures |
“(3R)” and “(3S)” in Claim 1 entries; dependent Claims 2-8, etc. |
| Side-chain stereochemistry |
individual E or Z or mixtures |
Explicit in Claim 1 and multiple dependents (Claims 3-5, 4, 7-9, 11-12, etc.) |
| End-group on side chain |
multiple substituted piperazine variants |
4-methylpiperazine, piperazine, trimethylpiperazine (3S,5R), dimethylpiperazine (3S,5R), oxetan-3-yl piperazine |
| Core scaffold |
fixed pyrazolo[3,4-d]pyrimidine + 4-amino + 2-fluoro-4-phenoxyphenyl + carbonyl linkage + pent-2-enenitrile |
all listed compounds in Claim 1 share these features |
| Salt form |
pharmaceutically acceptable salts |
Claim 1: “and/or a pharmaceutically acceptable salt …” |
| Formulation |
composition claim with excipient |
Claim 13 and dependents 14-21 |
| Indication |
broad method-of-treatment categories |
Claim 22; specific autoimmune/inflammatory in Claim 23 |
| Manufacturing route |
aldehyde or vinyl-cyano acid/ester analog coupling with specified options |
Claim 30 process steps (a)-(f) |
Patent landscape implications: where enforcement pressure likely lands
Without external bibliographic and citation data (priority date, assignee, family members, examiner citations, expiration dates, and litigation events), the landscape read below stays inside the structural facts embedded in the claim set you supplied.
1) Likely “cluster” coverage around one scaffold family
Because the patent includes:
- a broad genus (Claim 1)
- multiple species dependents (Claims 2-12)
- composition (Claims 13-21)
- therapeutic use (Claims 22-29)
- and process (Claim 30)
US 8,940,744 is built to behave like a family pivot. Even if only part of the chemical genus is infringed, composition and use claims can capture commercialization, and process claims can capture supply chain behavior.
2) Design-around pressure is on stereochemistry and end-group selection
Competitors attempting a design-around must avoid at least one of these claim-included attributes:
- the exact substituted piperazine variant specified (or a close substitute not literally covered)
- the required stereochemical patterns if the product is forced into a non-matching stereochemical category (though Claim 1 includes mixtures and individual E/Z isomers, which reduces freedom)
- the specific scaffold linkage pattern that defines the pyrazolo[3,4-d]pyrimidine-carbonyl-pent-2-enenitrile architecture
3) Generic pathways risk multi-front exposure
For a copycat to be “clean,” they need to clear multiple IP barriers:
- chemical identity infringement (Claim 1 and dependents)
- formulation infringement (Claim 13 and dependents)
- use infringement (Claim 22 and dependents)
- manufacturing infringement (Claim 30)
That is an unusually comprehensive claim portfolio for a single US grant.
Key Takeaways
- US 8,940,744 is a scaffold-centric patent with stereochemistry-rich coverage (piperidine 3R/3S, plus E/Z isomerism) and end-group diversity (multiple piperazine variants including oxetan-3-yl piperazine).
- Claim 1 is broad by genus and explicitly includes mixtures, individual E/Z isomers, and pharmaceutically acceptable salts.
- Dependent claims lock in species fallbacks around specific piperazine substitution patterns and stereochemical configurations.
- Commercial use is covered through composition claims (Claim 13) and method-of-treatment claims (Claim 22 and dependents) across autoimmune, inflammatory, and multiple cancer indications.
- Manufacturing is covered via Claim 30 process routes that attach multiple Rc-piperazine variants through aldehyde or vinyl-cyano acid/derivative coupling, with optional salt/free base and stereoisomer separation steps.
FAQs
1) Does Claim 8,940,744 cover mixtures of stereoisomers?
Yes. Claim 1 includes mixtures of the (3R)- and (3S)-piperidine variants and includes coverage for E/Z isomers, including mixtures via dependent claims. It also includes “an individual E or Z isomer” and pharmaceutically acceptable salts.
2) Are salts explicitly included in the compound scope?
Yes. Claim 1 expressly includes “a pharmaceutically acceptable salt of any of the above compounds.”
3) Does the patent protect only the chemical entity or also formulations and uses?
It protects all three. Claim 13 covers pharmaceutical compositions, and Claim 22 covers methods of treating a broad list of autoimmune, inflammatory, and cancer indications.
4) Is manufacturing protection present, or is it purely product and use?
Manufacturing protection is present. Claim 30 is a process claim that includes coupling steps with aldehyde RcCHO or vinyl-cyano acid/ester equivalents RcCH═C(CN)CO2H or RcCH═C(CN)COX, followed by optional salt and stereoisomer handling.
5) What are the main design-around levers suggested by the claim language?
The claim language channels design-around toward changing at least one of the following: the substituted piperazine end-group identity (including oxetan-3-yl), the required scaffold/connection pattern, or the stereochemical categories (3R/3S and E/Z) that the claims explicitly include, along with avoidance of the stated process steps in Claim 30.
References (APA)
[1] United States Patent 8,940,744 (claims as provided by user: compound, composition, method-of-treatment, and process claims).
